WO1995001357A1 - 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation - Google Patents
1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation Download PDFInfo
- Publication number
- WO1995001357A1 WO1995001357A1 PCT/HU1994/000024 HU9400024W WO9501357A1 WO 1995001357 A1 WO1995001357 A1 WO 1995001357A1 HU 9400024 W HU9400024 W HU 9400024W WO 9501357 A1 WO9501357 A1 WO 9501357A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- benzodiazepine
- dihydro
- methylenedioxy
- nitrophenyl
- Prior art date
Links
- DJXIVFHYOLZSBW-UHFFFAOYSA-N 8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine Chemical compound N=1NC(C)CC2=CC=3OCOC=3C=C2C=1C1=CC=C([N+]([O-])=O)C=C1 DJXIVFHYOLZSBW-UHFFFAOYSA-N 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 41
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims abstract description 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910000085 borane Inorganic materials 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- -1 aliphatic halo- hydrocarbon Chemical class 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 19
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000003579 shift reagent Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229940049706 benzodiazepine Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 5
- 102000003678 AMPA Receptors Human genes 0.000 description 4
- 108090000078 AMPA Receptors Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 3
- RNQRLYWVOJJHKD-UHFFFAOYSA-N 8-methyl-5-(4-nitrophenyl)-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 RNQRLYWVOJJHKD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- VGLKHVQPWGFXEG-NCJHBDPTSA-K europium(3+);(1z)-2,2,3,3,4,4,4-heptafluoro-1-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)butan-1-olate Chemical compound [Eu+3].C1CC2(C)C(=O)\C(=C(/[O-])C(F)(F)C(F)(F)C(F)(F)F)C1C2(C)C.C1CC2(C)C(=O)\C(=C(/[O-])C(F)(F)C(F)(F)C(F)(F)F)C1C2(C)C.C1CC2(C)C(=O)\C(=C(/[O-])C(F)(F)C(F)(F)C(F)(F)F)C1C2(C)C VGLKHVQPWGFXEG-NCJHBDPTSA-K 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- UICJTWHIOCCXDG-UHFFFAOYSA-N n,8-dimethyl-5-(4-nitrophenyl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide Chemical compound C12=CC=3OCOC=3C=C2CC(C)N(C(=O)NC)N=C1C1=CC=C([N+]([O-])=O)C=C1 UICJTWHIOCCXDG-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- 150000000179 1,2-aminoalcohols Chemical class 0.000 description 2
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 0 *C(*)(C(c1ccccc1)(N)O)N Chemical compound *C(*)(C(c1ccccc1)(N)O)N 0.000 description 1
- SMGACXZFVXKEAX-UHFFFAOYSA-N 5-(4-aminophenyl)-n,8-dimethyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide Chemical compound C12=CC=3OCOC=3C=C2CC(C)N(C(=O)NC)N=C1C1=CC=C(N)C=C1 SMGACXZFVXKEAX-UHFFFAOYSA-N 0.000 description 1
- YVOHCRLDUPTKOH-UHFFFAOYSA-N 5h-2,3-benzodiazepine Chemical class C1C=NN=CC2=CC=CC=C12 YVOHCRLDUPTKOH-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical class [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Definitions
- OPTICALLY ACTIVE 1- (4-NITROPHENYL) -4-METHYL-7 , 8- -METHYLENEDIOXY-3 - 4-DIHYDRO-5H-2 , 3-BENZODIAZEPINE AND PROCESS FOR PREPARING SAME
- This invention relates to the enantiomers of l- (4- nitrophenyl) -4-methyl-7 , 8-methylenedioxy-3 , 4-dihydro-5H- -2 , 3-benzodiazepine of the formula (I)
- -benzodiazepines e.g. the l-(4-aminophenyl)-3-acetyl-4- -methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodi- azepine and l-(4-aminophenyl)-3-(N-methylcarbamoyl)-4- -methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodi- azepine, possess anticonvulsive, muscle relaxant and neuroprotective effects.
- the basis of these valuable pharmacological effects is a noncompetitive antagonism of quisqualate/AMPA receptors.
- l-(4-amino- phenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3- -benzodiazepine and l-(4-acetylaminophenyl)-4-methyl-7,8- -methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine are dopamine-uptake-inhibiting and psychostimulatory in their character; therefore, these compounds may potentially be useful for the treatment of parkinsonism. These compounds have chiral structure.
- the most preferred possibility of preparing optically pure enantiomers consists in that the enantiomers of the first chiral molecule of the synthesis, in the given case the compound of formula (I) , are prepared and the subsequent steps of the synthesis are carried out by starting from these enantiomers.
- the traditional resolution based on the separation of diastereomeric salt or compound pairs can theoretically provide the pure enantiomers of a racemic compound in a yield of at most 50%
- the desired enantiomer(s) can be prepared in yields substantially higher than 50 %.
- the invention is aimed at providing a process, by which the double bond in 3,4-position of the achiral derivative of formula (II)
- the peparation of enan- tiomers of 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy- -3,4-dihydro-5H-2,3-benzodiazepine of formula (I) com ⁇ prises reducing 1-(4-nitrophenyl)-4-methyl-7,8-methylene- dioxy-5H-2,3-benzodiazepine of formula (II) by using an adduct formed from an (R)- or (S)-, respectively, 2- -amino-1,1-diphenylalkan-l-ol derivative of formula (III), wherein R l and R2, which are different, stand for hydrogen; a straight or branched chain C ⁇ -4 alkyl group; or an unsubstituted phenyl or benzyl group, with one molar equivalent of borane or a borane complex.
- the enantiomers of the compound of formula (I) are valuable intermediates which, after acylation and subsequent reduction, lead to the enantio ⁇ mers of l-(4-aminophenyl)-3-acyl-4-methyl-7,8-methylene- dioxy-3,4-dihydro-5H-2,3-benzodiazepines, which are anta ⁇ gonists of the quisqualate/AMPA receptors; or, by reduc ⁇ ing and then, if desired, acetylating the enantiomers of the compound of formula (I), l-(4-aminophenyl)-4-methyl- -7,8-methylenedioxy-3,4-dhydro-5H-2,3-benzodiazepine and 1-(4-acetylaminophenyl)-4-methyl-7,8-methylenedioxy-3, - -dihydro-5H-2,3-benzodiazepine can be obtained, which have psychostimulant character.
- the reaction mixture is suitably worked up as follows: the mixture is mixed with sodium carbonate solution, the organic phase is washed with water until neutral and evaporated under reduced pressure.
- the crystalline product obtained is suspended in a C 1 _ 3 al- kanol, preferably ethanol, and the product is isolated by filtration.
- the primary product obtained is characterized by its specific rotary power.
- the enantiomeric purity of the product is qualified by the percentage of enantiomers, which can be determined by the following methods: 1) by ⁇ -H-N R techniques using a complex of para ⁇ magnetic rare earth element (shift reagent) ; or
- the primary product has a high enantiomeric purity, which can be in ⁇ creased nearly to 100% even by a single recrystalliza- tion.
- Example 1 The invention is illustrated in detail by the following non-limiting Examples.
- Example 1 The invention is illustrated in detail by the following non-limiting Examples.
- the ratio of (-) enantiomer to the (+) enantiomer was found to be 90:10 as determined by 1 H-NMR spectro- scopy by using Eu(hfc) 3 shift reagent (by weighing 5 mg of shift reagent to 10 mg of substance and dissolving this mixture in deuterochloroform) .
- Example 2 (Daicel Chemical Industries, LTD)] with a 35:65 mixture of hexane and isopropanol as eluent.
- Example 2 Method A
- the therapeutically valuable products may be pre ⁇ pared from the enantiomers of formula (I) according to the invention e.g. in the following way.
- 1. Preparation of (+)-l-(4-aminophenyl)-3-acetyl- -4-methyl-7,8-methylenedioxy-3, -dihydro-5H-2 ,3- -benzodiazepine Step a)
- (+)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methy- lenedioxy-3 ,4-dihydro-5H-2 ,3-benzodiazepine To a suspension containing 2.6 g (7.08 mmol) of (-)-l-(4-nitrophenyl)-3-acetyl-4-methyl-7,8-methylene- dioxy-3,4-dihydro-5H-2,3-benzodiazepine in 52 ml of methanol, 0.5 g of wet Raney nickel catalyst and 1.2 ml (24.8 mmol) of 100% hydrazine hydrate were added and the reaction mixture was stirred for 1 hour.
- This product contained the minor enantiomer in an amount lower than 1% (based on HPLC analysis and 1 H-NMR shift reagent method) .
- This product contained the minor enantiomer in an amount lower than 1% (HPLC: CHIRALCEL OF by using a 1:1 mixture of n-hexane and isopropanol containing 0.1% by vol. of diethylamine as eluent; 1 H-NMR: 10 ml of product + + 10 or 20 mg of Eu(hfc) 3 shift reagent in deutero- chloroform) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne les énantiomères -(+) et les énantiomères -(-) du composé dont la formule est indiquée en (I), ainsi qu'un procédé de préparation de ces énantiomères. Ce procédé implique la réduction du 1-(4-nitrohényl)-4-méthyl-7,8-méthylènedioxy-5H^_-2,3-benzodiazépine dont la formule est indiquée en (II); on utilise à cette fin un composé d'addition obtenu à partir d'un dérivé 2-aminé-1,1-diphényl-alcane-1-ol respectivement-(R) ou -(S) dont la formule est indiquée en (III), où R1 et R2, qui sont différents, représentent un groupe alkyle C1-4 à chaîne droite ou ramifiée, ou un groupe phényle ou benzyle non substitué, comportant un équivalent molaire de borane ou un complexe de borane. Les énantiomères du composé dont la formule est indiquée en (I) constituent de précieux intermédiaires intervenant dans la synthèse des composés actifs sur le plan thérapeutique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72363/94A AU7236394A (en) | 1993-07-02 | 1994-06-30 | Optically active 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h -2,3-benzodiazepine and process for preparing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP9301922 | 1993-07-02 | ||
HU9301922A HU219777B (hu) | 1993-07-02 | 1993-07-02 | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995001357A1 true WO1995001357A1 (fr) | 1995-01-12 |
Family
ID=10983751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU1994/000024 WO1995001357A1 (fr) | 1993-07-02 | 1994-06-30 | 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7236394A (fr) |
HU (1) | HU219777B (fr) |
WO (1) | WO1995001357A1 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0699677A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Procédé stéréosélectif pour la préparation de dérivés de dihydro-2,3-benzodiazépine |
EP0699678A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Forme cristalline d'un dérivé de dihydro-2,3-benzodiazépine |
EP0699676A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Forme physique d'un dérivé de dihydro-2,3-benzodaizépine |
US5665878A (en) * | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
WO1999007707A1 (fr) * | 1997-08-12 | 1999-02-18 | EGIS Gyógyszergyár Rt. | DERIVES DE 9H-1,3-DIOXOLO/4,5-h//2,3/BENZODIAZEPINE SUBSTITUEE EN HUIT UTILISES COMME INHIBITEURS DES RECEPTEURS D'AMPA/KAINATE |
WO1999007708A1 (fr) * | 1997-08-12 | 1999-02-18 | EGIS Gyógyszergyár Rt. | Derives de 1,3-dioxolo/4,5-h//2,3/benzodiazepine utilises comme inhibiteurs des recepteurs ampa/kainate |
WO2001004122A3 (fr) * | 1999-07-07 | 2001-05-10 | Egyt Gyogyszervegyeszeti Gyar | Nouveaux derives de 2,3-benzodiazepines |
EP1157992A1 (fr) * | 1994-08-31 | 2001-11-28 | Eli Lilly And Company | Dérivés de dihydro-2,3-benzodiazépine |
US6649607B2 (en) | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
US6825192B1 (en) | 1999-02-15 | 2004-11-30 | Eisai Co., Ltd. | Heterodiazinone derivatives |
US6858605B2 (en) | 2003-02-04 | 2005-02-22 | Ivax Drug Research Institute, Ltd. | Substituted 2,3-benzodiazepine derivatives |
US6949571B2 (en) | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
US7759367B2 (en) | 2001-12-06 | 2010-07-20 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions and their uses |
US8304548B2 (en) | 2004-07-06 | 2012-11-06 | Eisai R&D Management Co., Ltd. | Method for producing 1, 2-dihydropyridine-2-one compound |
WO2020124090A1 (fr) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine |
US12303499B2 (en) | 2019-12-16 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0492485A1 (fr) * | 1990-12-21 | 1992-07-01 | Gyogyszerkutato Intezet | Dérivés de N-acyl-2,3-benzodiazépine, compositions pharmaceutiques les contenant et procédé pour leur préparation |
WO1992011262A1 (fr) * | 1990-12-21 | 1992-07-09 | Gyógyszerkutató Intézet K.V. | Derives de 1-(4-acylaminophenyl)-7,8-methylenedioxy-5h-2,3-benzo-diazepine, leurs sels d'addition d'acides, compositions pharmaceutiques les contenant, et leur procede de preparation |
-
1993
- 1993-07-02 HU HU9301922A patent/HU219777B/hu not_active IP Right Cessation
-
1994
- 1994-06-30 WO PCT/HU1994/000024 patent/WO1995001357A1/fr active Application Filing
- 1994-06-30 AU AU72363/94A patent/AU7236394A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0492485A1 (fr) * | 1990-12-21 | 1992-07-01 | Gyogyszerkutato Intezet | Dérivés de N-acyl-2,3-benzodiazépine, compositions pharmaceutiques les contenant et procédé pour leur préparation |
WO1992011262A1 (fr) * | 1990-12-21 | 1992-07-09 | Gyógyszerkutató Intézet K.V. | Derives de 1-(4-acylaminophenyl)-7,8-methylenedioxy-5h-2,3-benzo-diazepine, leurs sels d'addition d'acides, compositions pharmaceutiques les contenant, et leur procede de preparation |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329364B1 (en) | 1994-08-31 | 2001-12-11 | Eli Lilly And Company | Crystalline form of dihydro-2,3-benzodiazepine derivative |
EP0699678A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Forme cristalline d'un dérivé de dihydro-2,3-benzodiazépine |
EP0699676A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Forme physique d'un dérivé de dihydro-2,3-benzodaizépine |
US5665878A (en) * | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
EP1593683A3 (fr) * | 1994-08-31 | 2006-10-25 | Eli Lilly And Company | Dérivés de dihydro-2,3-benzodiazépine |
EP0699677A1 (fr) * | 1994-08-31 | 1996-03-06 | Eli Lilly And Company | Procédé stéréosélectif pour la préparation de dérivés de dihydro-2,3-benzodiazépine |
AU702658B2 (en) * | 1994-08-31 | 1999-02-25 | Eli Lilly And Company | Stereoselective process for producing dihydro-2, 3-benzodiazepine derivatives |
US5919954A (en) * | 1994-08-31 | 1999-07-06 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
US5986114A (en) * | 1994-08-31 | 1999-11-16 | Eli Lilly And Company | Benzopyranol derivatives |
CN1086705C (zh) * | 1994-08-31 | 2002-06-26 | 伊莱利利公司 | 制备二氢-2,3-苯并二氮杂䓬衍生物立体有择方法和中间体 |
US6288057B1 (en) | 1994-08-31 | 2001-09-11 | Eli Lilly And Company | Physical form of dihydro-2,3-benzodiazepine derivative |
CN1073995C (zh) * | 1994-08-31 | 2001-10-31 | 伊莱利利公司 | 二氢-2,3-苯并二氮杂䓬衍生物的物理形态,制备方法和用途 |
CN1073996C (zh) * | 1994-08-31 | 2001-10-31 | 伊莱利利公司 | 二氢-2,3-苯并二氮杂䓬衍生物的物理形态,制备方法和用途 |
EP1157992A1 (fr) * | 1994-08-31 | 2001-11-28 | Eli Lilly And Company | Dérivés de dihydro-2,3-benzodiazépine |
US6562810B1 (en) | 1997-08-12 | 2003-05-13 | Egis Gyogyszergyar Rt. | 8-substituted-9H-1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives, as AMPA/kainate receptor inhibitors |
WO1999007708A1 (fr) * | 1997-08-12 | 1999-02-18 | EGIS Gyógyszergyár Rt. | Derives de 1,3-dioxolo/4,5-h//2,3/benzodiazepine utilises comme inhibiteurs des recepteurs ampa/kainate |
WO1999007707A1 (fr) * | 1997-08-12 | 1999-02-18 | EGIS Gyógyszergyár Rt. | DERIVES DE 9H-1,3-DIOXOLO/4,5-h//2,3/BENZODIAZEPINE SUBSTITUEE EN HUIT UTILISES COMME INHIBITEURS DES RECEPTEURS D'AMPA/KAINATE |
US6825192B1 (en) | 1999-02-15 | 2004-11-30 | Eisai Co., Ltd. | Heterodiazinone derivatives |
WO2001004122A3 (fr) * | 1999-07-07 | 2001-05-10 | Egyt Gyogyszervegyeszeti Gyar | Nouveaux derives de 2,3-benzodiazepines |
US7939549B2 (en) | 2000-06-12 | 2011-05-10 | Eisai R&D Management Co., Ltd. | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
US6949571B2 (en) | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
EP2053041A2 (fr) | 2000-06-12 | 2009-04-29 | Eisai R&D Management Co., Ltd. | 2(1H)-Pyridones 1,3,5-trisubstituées commes inhibiteurs du récepteur AMPA utilisables pour le traitement par ex. de la maladie de Parkinson |
US7563811B2 (en) | 2000-06-12 | 2009-07-21 | Eisai R&D Management Co., Ltd. | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
US6649607B2 (en) | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
US7078398B2 (en) | 2001-05-18 | 2006-07-18 | Vela Pharamaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
US7759367B2 (en) | 2001-12-06 | 2010-07-20 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions and their uses |
US6858605B2 (en) | 2003-02-04 | 2005-02-22 | Ivax Drug Research Institute, Ltd. | Substituted 2,3-benzodiazepine derivatives |
US8304548B2 (en) | 2004-07-06 | 2012-11-06 | Eisai R&D Management Co., Ltd. | Method for producing 1, 2-dihydropyridine-2-one compound |
US8772497B2 (en) | 2004-07-06 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Method for producing 1, 2-dihydropyridine-2-one compound |
US9045426B2 (en) | 2004-07-06 | 2015-06-02 | Eisai R&D Management Co., Ltd. | Method for producing 1,2-dihydropyridine-2-one compound |
WO2020124090A1 (fr) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine |
US12303499B2 (en) | 2019-12-16 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Also Published As
Publication number | Publication date |
---|---|
AU7236394A (en) | 1995-01-24 |
HUT67611A (en) | 1995-04-28 |
HU219777B (hu) | 2001-07-30 |
HU9301922D0 (en) | 1993-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995001357A1 (fr) | 1-(4-nitrophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h2-,3 -benzodiazepine optiquement actif et procede de preparation | |
US5536832A (en) | N-acyl-2,3-benzodiazepine derivatives pharmaceutical compositions containing them and process for preparing same | |
EP0362695B1 (fr) | Dérivés de pyrrolocarbazole, procédés de leur préparation et leur application comme médicaments | |
EP0266349B1 (fr) | Derives d'indole tricycliques, fabrication et utilisation comme medicaments | |
WO1993000337A1 (fr) | Acides (s)(+)-2-ethoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoique | |
JPS60358B2 (ja) | ベンゾモルフアン化合物の製法 | |
JPH05194511A (ja) | ピラゾール環がアルキル化されたピラゾロキノリン類 | |
US4235775A (en) | Triazolobenzodiazepine derivatives | |
FR2553409A1 (fr) | Nouveaux benzenesulfonyl-lactames, leur procede de preparation et leur application comme substance active de compositions pharmaceutiques | |
CA1250582A (fr) | Derives de tetrahydrocorynantheine et preparation | |
BE1009852A3 (fr) | Derives 1-[2(vinyl-substitues)]-3-4-dihydro-5h-2,3-benzodiazepine. | |
EP1444234A2 (fr) | Pyrazolopyrimidinones deuterees et medicaments contenant ces composes | |
EP0718299B1 (fr) | Ethers d'oximes tricycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
JPS5912678B2 (ja) | 新規のピリミジン誘導体の製造方法 | |
WO1999011646A1 (fr) | Analogues optiquement purs de la camptothecine, intermediaire de synthese optiquement pur et son procede de preparation | |
EP0160451B1 (fr) | Isomères d'esters d'acides dihydropyridine-3,5-dicarboxyliques, leur procédé de préparation et les compositions pharmaceutiques les contenant | |
TW200413301A (en) | Improved process for the preparation of 1,3-substituted indenes | |
JPH06122686A (ja) | ラセミ体の光学分割法 | |
CN101466680A (zh) | 合成哌嗪-哌啶化合物的方法 | |
CA2346506C (fr) | Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1 | |
CA2021737C (fr) | Synthese asymmetrique de derives de furo¬3,4-c|pyridine | |
Beal et al. | An efficient, one-pot synthesis of 3-alkyl or aryl sydnoneimines | |
JPH02289581A (ja) | 光学的に純粋なヘトラゼピン類の改良された製造方法 | |
GB1567997A (en) | Biologically active tetracyclic compounds and pharmaceutical compositions containing same | |
JPH07500571A (ja) | Pcpレセプター・リガンドおよびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |